Bull & Bear

Bull and Bear

Verdict: Watchlist — the bear has the more current and concrete evidence (operating leverage running in reverse, full-price sales/sqft -9.4%, Power of Three x2 missed by $1.1B), while the bull has the better setup (9.4x P/E with 31% ROIC, $1.8B cash and zero funded debt, two CEO catalysts inside twelve months). The decisive question is whether the U.S. women's deterioration is a cyclical inventory/assortment cycle or structural brand erosion — and that question is not answerable from today's evidence. Both sides agree on the forcing function: Q1 FY26 (early June 2026) and Q2 FY26 (September 2026) prints will resolve it inside 4-16 weeks. Buying ahead of an unproven inflection that management has mis-called three times in 18 months is poor risk/reward; selling a fortress balance sheet at trough multiples is also poor risk/reward. Wait for the print.

Bull Case

Bull-case fair value: ~$215 (12-18 months) via 16x normalized EPS of approximately $13.50, anchored to FY25 actual $13.26 with modest buyback accretion. The 16x multiple sits halfway between LULU's prior-decade trough and Deckers' current 14.7x; an 11x EV/EBIT cross-check on a through-cycle 22% operating margin converges at roughly $222. Primary catalyst: Q2 FY26 earnings (September 2026), the first print under co-CEOs ahead of Heidi O'Neill's start, where management's own guide calls for North America full-price selling to inflect flat-to-positive. Disconfirming signal: Q2 FY26 Americas comparable sales worse than -3% with markdown penetration up another 100+ bps — consistent with structural erosion.

Bear Case

Bear-case fair value: ~$90 (12-15 months) via P/E compression to 8x on FY26 bear EPS of approximately $11.30, anchored to the explicit bear-case EPS if NA comps stay negative and gross margin compresses another 200 bps. The 8x multiple sits mid-band between COLM 12.3x and UAA negative as quality drops; an EV/sales cross-check at COLM-style 0.89x on $11.4B revenue lands at roughly $100. Primary trigger: Q1 FY26 earnings (early June 2026, approximately 4 weeks from today). A print in line with or worse than the mid-single-digit Americas decline guide — particularly markdowns up another 100+ bps, gross margin under 55% ex-tariff, or evidence Q2 full-price flat is at risk — would push sell-side EPS toward $11. Cover signal: two consecutive quarters of positive Americas comparable sales paired with rising full-price penetration and FY26 gross margin holding above 56% — i.e., management's own guide actually delivered. Either alone is not enough.

The Real Debate

Verdict

Watchlist. The bear carries more weight today because the evidence is concrete and current — operating profit fell 12% on a 5% revenue gain, full-price sales/sqft dropped 9.4%, the five-year plan was missed by $1.1B, and management's own root-cause diagnosis has reset three times in 18 months. The bull case rests on a trough multiple and a fortress balance sheet, both real, but it requires believing in an inflection that management has mis-called three times. The decisive tension is cyclical-vs-structural: Q1 FY26 (early June 2026) and Q2 FY26 (September 2026) prints will answer it inside 4-16 weeks, with both advocates agreeing on the forcing data — Americas comparable sales and full-price penetration. The bull case has support: the international engine ($740M of incremental FY25 revenue at 29%/16% growth) genuinely backfills the Americas drag, the buyback authorization compounds at sub-10x with 31% ROIC, and a product-led reset under a credible Nike-trained operator fits the diagnosed problem. The verdict shifts toward Lean Long if Q1 FY26 prints in line with or better than guide AND markdown penetration declines or holds — that would end the diagnostic-clock-resetting and leave substantial room for multiple expansion off trough. The verdict shifts to Avoid if Q1 FY26 markdowns rise another 100+ bps or gross margin breaks 55% ex-tariff, validating the structural-impairment frame.